Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research[1][2][3].
Molecular Weight:
2055.49 (free base)
Formula:
C90H163N27O25S.xC2HF3O2
Target:
Apoptosis
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
